回復期患者血漿

Effectiveness of convalescent plasma therapy in severe COVID-19 patients.
 Duan K, et al.〔Proc Natl Acad Sci U S A. 2020 Apr 6.〕（査読済み）


Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
 Shen C, et al.〔JAMA. 2020 Mar 27〕（査読済み）

Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection.
 Zhang B, et al.〔Chest. 2020 Mar 31〕（査読済み）

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.
 Li L, et al.〔JAMA. 2020 Jun 3〕（査読済み）

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
 Libster R, et al.〔N Engl J Med. 2021; 384:610-618〕（査読済み）

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
 Joyner MJ, et al.〔N Engl J Med. 2021; 384:1015-1027〕（査読済み）

Efficacy of convalescent plasma therapy for COVID‐19: A systematic review and meta‐analysis
 Vegivinti CTR, et al.〔J Clin Apher. 2021 Feb 5;10.1002/jca.21881〕（査読済み）

Safety and efficacy of convalescent plasma in elderly COVID-19 patients: the RESCUE trial
 Franchini M, et al.〔Mayo Clin Proc Innov Qual Outcomes. 2021 Feb 8〕（査読済み）

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
 Wibmer CK, et al.〔Nat Med. 2021 Apr;27(4):622-625〕（査読済み）

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
 Chen RE, et al.〔Nat Med. 2021 Apr;27(4):717-726〕（査読済み）

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
 Planas D, et al.〔Nat Med. 2021 Mar 26〕（査読済み）

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
 RECOVERY Collaborative Group〔Lancet. 2021 May 29;397(10289):2049-2059〕（査読済み）